Feasibility and Clinical Value of CT-guided<sup>125</sup>I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma

Wang, Guobao; Zhang, Fujun; Yang, Bin; Xue, Jing; Peng, Sheng; Zhong, Zhihui; Zhang, Tao; Lu, Mingjian; Gao, Fei

doi:10.1148/radiol.2015150641

Cited by 26 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have indicated that MWA is an effective, feasible, and minimally invasive treatment for early stage of NSCLC . Brachytherapy has demonstrated good local control for salvage therapy of recurrent lung malignancies after failure of chemotherapy or radiotherapy . Theoretically, both procedures are capable of destroying small recurrences of NSCLC with a diameter <4 cm.…”

Section: Discussionmentioning

confidence: 99%

“…Compared with RFA, MWA demonstrated faster ablation times, larger ablation zones, and higher intratumoral temperatures in ex and in vivo animal models, as well as human patients, which brings broad indications. Iodine‐125 seed brachytherapy has been demonstrated to be a feasible and effective treatment for lung tumors, with a good local control rate and improved disease‐free survival (DFS) . To the best of our knowledge, there has been no research which has compared MWA and iodine‐125 seed brachytherapy as a salvage treatment for local recurrence of NSCLC after failure of first‐line chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

et al. 2020

View full text Add to dashboard Cite

Background Salvage treatments for recurrent NSCLC after first‐line chemotherapy remain challenging. This study was conducted to evaluate the clinical value of microwave ablation (MWA) and iodine‐125 brachytherapy, including overall survival (OS), disease free survival (DFS), local control, hospital stay, and health economics. Methods The data of 51 and 32 patients who were treated with MWA and brachytherapy was retrospectively analyzed. The number of lesions was limited up to two, with a diameter <4 cm and patients diagnosed with unilateral lung disease. Peripheral tumors were treated with MWA, while lesions close to the hilum were treated with brachytherapy. Contrast‐enhanced CT, blood cell count, coagulation function, liver & kidney function and tumor markers were performed for two years, with complications calculated. OS, DFS, local control rate, toxicity, hospital stay and expense were recorded. Results The one and two‐year OS rates were 96.08% and 92.16% versus 96.88% and 90.62% in the MWA and brachytherapy groups, respectively. The one and two‐year DFS rates were 92.16% and 76.47% versus 93.75% and 78.13%, respectively. No significant differences were observed in log‐rank analysis between the groups. Local control rates at six and 12 months were 100% and 96.08% versus 100% and 96.88%, while incidences of pleural effusion were 3.92% and 3.13%, respectively (P < 0.05). Medical cost was 3356.73 ± 206.87 and 6714.28 ± 35.43 U.S. dollars (P = 0.014). Conclusion MWA and brachytherapy are effective and safe options for the treatment of NSCLC recurrence after first‐line chemotherapy. Which modality should be considered is dependent upon tumor location, tumor size and experience of specialists.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Understandably, the therapeutic efficacy of surgical treatment combined with external radiotherapy and/or chemotherapy is inadequate and unsatisfactory. Three-dimensional stereotactic radiotherapy using interstitial implantation of 125 I seeds is now considered a novel complement to surgery and external radiotherapy [2, 3, 4]. …”

Section: Purposementioning

confidence: 99%

Computed tomography-guided implantation of 125 I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results

Zhang

et al. 2017

jcb

View full text Add to dashboard Cite

PurposeTo retrospectively evaluate the efficacy and safety of computed tomography (CT)-guided percutaneous interstitial brachytherapy using 125I radioactive seeds for multiple pulmonary metastatic tumors.Material and methodsBetween September 2013 and December 2015, 22 patients with multiple pulmonary metastases, who after conventional chemotherapy and trans-arterial chemoembolization (TACE) therapy were considered unable to withstand stereotactic body radiation therapy (SBRT), received CT-guided 125I brachytherapy. Clinical data were studied retrospectively. A planning target volume of 90% (D90) was 120-160 Gy for 125I seeds with an activity of 25.9 MBq. A CT-based evaluation performed 1, 2, and 6 months’ post-implantation enabled review of local control of tumors.ResultsTwenty-two patients with 65 pulmonary metastases successfully completed treatment. The mean value for D90 for implantation for 125I seeds was 132 Gy. Complete response (CR) + partial response (PR) was documented in 81.54%, 78.46%, and 78.46% of patients at 1, 2, and 6 months after implantation, respectively. Fourteen out of 22 patients had CR, 3 had PR, 2 had stable disease (SD), and 3 had progressive disease (PD). Most of the metastases (CR + PR + SD; 87.69% after 6 months) were controlled by implantation.ConclusionsCT-guided 125I brachytherapy is a safe and effective treatment for multiple pulmonary metastatic tumors, and can achieve good short-term local control, so long as the radiation dose is sufficient.

show abstract

“…Many studies have evaluated 125 I brachytherapy have a good curative effect in pancreatic cancer, liver cancer, lung cancer, prostate cancer, and gynecological and brain malignancies [14]. The 125 I seed is a miniature radioactive source; it continuously delivers low doses of x-rays and γ-rays, and the radiation dose decreases rapidly with increasing distance from the source [15].…”

Section: Introductionmentioning

confidence: 99%

CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region

Yan

Xiang²,

Zhong³

et al. 2017

Translational Oncology

Self Cite

View full text Add to dashboard Cite

PURPOSE: We aimed to evaluate the feasibility and clinical effectiveness of CT-guided 125I brachytherapy for distant oral and maxillofacial metastases. MATERIALS AND METHODS: We retrospectively analyzed 65 patients with 84 distant oral and maxillofacial metastases. Thirty-one patients with 38 lesions received 125I brachytherapy (group A) and 34 with 46 lesions received external beam radiotherapy (EBRT; group B). RESULTS: Median follow-up time was 16 months. The 3-, 6-, 12-, 18-, and 24-month local control rates for group A were 83.9%, 75.9%, 66.7%, 38.4%, and 25.0%, respectively; for group B they were 76.5%, 62.5%, 43.8%, 25.0%, and 0.0%, respectively (P < .05); the median local tumor progression-free survival times were 14 and 9 months, respectively. Group A had a better local tumor progression-free survival (LTPFS) relative to group B (P < .001; HR, 6.961 [95%CI, 2.109, 9.356]). Cox proportional hazards regression analysis indicated that 125I brachytherapy, tumor size, and primary pathological type were the independent factors affecting LTPFS. Additionally, 125I brachytherapy showed better performance in relieving patient clinical symptoms relative to EBRT (P < .05). Group A also had fewer complications than group B, especially regarding grade 3/4 complications according to Radiation Therapy Oncology Group grading criteria. Mean overall survival times in groups A and B were 17.1 and 14.8 months, respectively. CONCLUSION: CT-guided 125I brachytherapy is feasible and safe for distant oral and maxillofacial metastases; it achieved a better local control rate, longer LTPFS and fewer complications without compromising overall survival compared with EBRT.

show abstract

Feasibility and Clinical Value of CT-guided¹²⁵I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma

Abstract: CT-guided (125)I brachytherapy is feasible and safe for the treatment of bilateral lung recurrences from colorectal carcinoma.

Cited by 26 publications

References 26 publications

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

Computed tomography-guided implantation of 125 I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results

CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region

Contact Info

Product

Resources

About

Feasibility and Clinical Value of CT-guided125I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma

Abstract: CT-guided (125)I brachytherapy is feasible and safe for the treatment of bilateral lung recurrences from colorectal carcinoma.

Cited by 26 publications

References 26 publications

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

Salvage treatment of NSCLC recurrence after first‐line chemotherapy failure: Iodine‐125 seed brachytherapy or microwave ablation?

Computed tomography-guided implantation of 125 I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results

CT-guided 125I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region

Contact Info

Product

Resources

About

Feasibility and Clinical Value of CT-guided¹²⁵I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma